Skip to main content

Advertisement

SpringerLink
Log in

Heterogeneity in Outcomes of Pathologic T1-2N1 Breast Cancer After Mastectomy: Looking Beyond Locoregional Failure Rates

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

A meta-analysis of 22 randomized trials accrued from 1964 to 1986 demonstrated significantly higher rates of locoregional failure (LRF) and breast-cancer mortality in women with 1–3 positive nodes without postmastectomy radiotherapy (PMRT) after mastectomy (mast.). Recent data demonstrate that PMRT reduces distant metastases (DM) in women with pN1 disease. The challenge today is whether all patients with pathologic T1-2pN1 disease have similar substantial LRF/DM risk that routinely warrants PMRT.

Methods

We reviewed patients with pT1-2N1 breast cancer treated with mast. ± adjuvant systemic therapy without PMRT from 2000 to 2013. The endpoints were LRF and DM rates, estimated by cumulative incidence method.

Results

We identified 468 patients with median follow-up of 6.3 years. Most (71%) were estrogen receptor/progesterone receptor + human epidermal growth factor receptor 2 (HER2). There were 269 patients with 1+ node, 140 patients with 2+ nodes, and 59 patients with 3+ nodes. The 6-year LRF/DM rates were 4.1%/8.4%. Patients with 1+, 2+, and 3+ nodes had 6-year LRF of 2.3, 5.1 and 8.9%, respectively (p = 0.13). The 6-year DM rate was higher in patients with 3+ nodes versus 1–2+ nodes: 15.7% versus 7.4% (p = 0.02). Several subgroups had low 6-year LRF and DM rates, including T1/1+ node (0.8%/4.1% LRF/DM) and micrometastases (0%/5.8% LRF/DM).

Conclusions

Patients with pT1-2pN1 represent a heterogeneous group with a wide range of LRF/DM rates. In particular, patients with pT1 tumors and 1 + LN, and patients with micrometastases, had low event rates. These groups would derive small absolute reductions in LRF and DM with addition of PMRT, underscoring the importance of patient selection for PMRT in pT1-2pN1 breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–2135.

    Article  PubMed  CAS  Google Scholar 

  2. McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89(2):392–398.

    Article  PubMed  Google Scholar 

  3. Miyashita M, Tada H, Suzuki A, et al. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era. Surg Oncol. 2017;26(2):163–170.

    Article  PubMed  Google Scholar 

  4. Moo TA, McMillan R, Lee M, et al. Selection criteria for postmastectomy radiotherapy in T1–T2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol. 2013;20(10):3169–3174.

    Article  PubMed  Google Scholar 

  5. Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–327.

    Article  PubMed  CAS  Google Scholar 

  6. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–316.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016;34(36):4431–4442.

    Article  PubMed  Google Scholar 

  8. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106.

    Article  PubMed  CAS  Google Scholar 

  9. Zeidan YH, Habib JG, Ameye L, et al. Postmastectomy radiation therapy in women with T1–T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018;101(2):316–324.

    Article  PubMed  Google Scholar 

  10. He ZY, Wu SG, Zhou J, et al. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1–2 and 1 to 3 positive nodes. PLoS ONE. 2015;10(3):e0119105.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1–3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83(5):e577–e581.

    Article  PubMed  Google Scholar 

  12. Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

    Article  PubMed  CAS  Google Scholar 

  14. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–1834.

    Article  PubMed  Google Scholar 

  15. Gluz O, Nitz UA, Christgen M, et al. West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34(20):2341–2349.

    Article  PubMed  Google Scholar 

  16. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–4071.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Woodward WA, Barlow WE, Jagsi R, et al. The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814. Int J Radiat Oncol Biol Phys. 2016;96(2):146.

    Article  Google Scholar 

  18. Mamounas EP, Liu Q, Paik S, et al. 21-Gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw259.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Canadian Cancer Trials Group. 2018. https://www.ctg.queensu.ca/public/breast/breast-disease-site. Accessed 6 March 2018.

Download references

Author information

Authors and Affiliations

  1. Departments of Radiation Oncology, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    Jose G. Bazan MD MS, Lonika Majithia MD, Allison M. Quick MD, Jessica L. Wobb MD & Julia R. White MD

  2. Departments of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA

    Alicia M. Terando MD, Doreen M. Agnese MD & William Farrar MD

Authors
  1. Jose G. Bazan MD MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lonika Majithia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allison M. Quick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jessica L. Wobb MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alicia M. Terando MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Doreen M. Agnese MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William Farrar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Julia R. White MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose G. Bazan MD MS.

Ethics declarations

Disclosure

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 391 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bazan, J.G., Majithia, L., Quick, A.M. et al. Heterogeneity in Outcomes of Pathologic T1-2N1 Breast Cancer After Mastectomy: Looking Beyond Locoregional Failure Rates. Ann Surg Oncol 25, 2288–2295 (2018). https://doi.org/10.1245/s10434-018-6565-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6565-8

Keywords

Search

Navigation